An Engineered Protein Unlocks New Potential Therapies

Pieris has developed a new class of protein drug, called Anticalin, which can be engineered to bind to a multitude of potential therapeutic targets. This opens up the potential to develop therapies for a vast range of illnesses.

Their first successes were in immuno-oncology and asthma, with each application operating with its own mechanism of action. In the field of pharmacology, unless a drug’s mechanism of action is exceedingly simple or universally understood, the standard method for communicating a drug’s molecular action is through an animated video.

Pieris contacted Microverse Studios first to demonstrate the function of the fusion protein PRS-343, which is only triggered when in the presence of both tumor and T-cells. It then activates T-cells that have been made dormant by the tumor’s immune silencing but without the dangerous side effects of systemic immune activators.

After a brief science call and providing the Microverse team with all of the relevant scientific papers and data, the animators at Microverse Studios developed a storyline that would draw the viewer through the mechanism of action and leave them fully understanding the drug’s function.

The animation was such a good complement to their communications and branding strategy that Pieris came back to Microverse when they had developed a second application of their anticalin technology to treat severe asthma with a minimum of side effects.